For prescribing information, click here

This website has been commissioned by Ipsen Pharmaceuticals Ltd. and is intended for an Irish audience. If you are not a Healthcare Professional, please click here.
Adverse event reporting information is available at the bottom of this webpage.

This website has been commissioned by Ipsen Pharmaceuticals Ltd. and is intended for an Irish audience

Cabometyx® (Cabozantinib) therapeutic indications

Cabometyx® is indicated as monotherapy treatment of advanced renal cell carcinoma (RCC):

  • in first-line treatment of adult patients with intermediate or poor risk per IMDC criteria.
  • in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.

Cabometyx® in combination with nivolumab for the first-line treatment of RCC in adults.

In this video, Anne describes the beginning of her journey including how she was diagnosed, when her treatment started and how her healthcare professional supported her through her journey. She also shares some top tips for people going through the same.

View more videos in this series by clicking the link below.

My journey with renal cell carcinoma: Managing treatment - from a patient's perspective

My journey with renal cell carcinoma: Managing treatment - from a patient's perspective

In this video, Anne describes how she manages her treatment and associated side effects day-by-day including specific tips, resources and how her healthcare team have supported her.
Watch now
Resources

Adverse events should be reported.
Reporting forms and information can be found at www.hpra.ie or e-mail medsafety@hpra.ie.
The HPRA can also be contacted on +353 16764971. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on +353 1 8098256.

To access relevant information about Renal Cell Carcinoma, please choose one of the following options:

I am a healthcare professional in Ireland

This section is for healthcare professionals only. Contains promotional information

I am a healthcare professional in Ireland

Adverse events should be reported.
Reporting forms and information can be found at www.hpra.ie or e-mail medsafety@hpra.ie.
The HPRA can also be contacted on +353 16764971. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on +353 1 8098256.

I am a patient

This section provides information to support patients that have been prescribed Cabometyx® (cabozantinib) in Ireland. It is designed for patients in Ireland and should not replace the opinion provided by your healthcare professional or the details contained in the Patient Information Leaflet.

I am a patient

I am a member of the general public

This section is for members of the general public.

I am a member of the general public

Reporting of side effects:
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly to the HPRA. Reporting forms and information can be found at www.hpra.ie or email medsafety@hpra.ie. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on +353 1 8098256. By reporting side effects, you can help provide more information on the safety of this medicine.